From Pilot Program to Permanent Supply
Until the end of March 2026, France conducted a comprehensive experimental phase involving over three thousand patients. The goal was to test the prescription and effects of medical cannabis under strict clinical conditions.
📑 Inhaltsverzeichnis
With April 2026, this provisional period ends and transitions into a regular, nationwide legal framework. This step removes cannabis flowers and extracts from legal gray zones and anchors them firmly within the French healthcare system.
Strict Requirements for Prescription and Cultivation
Unlike other European countries, France adopts a strongly pharmaceutical-oriented approach. Cannabis therapy remains defined as a so-called last resort—it is used only when conventional standard therapies have failed or are not tolerated by patients.
Additionally, prescriptions cannot be issued by every general practitioner. Only specially trained and certified physicians receive authorization to issue corresponding prescriptions for their patients. Production also faces rigid requirements. For example, outdoor or greenhouse cultivation is strictly prohibited. Domestic producers may cultivate cannabis exclusively in strictly controlled indoor facilities and must demonstrate fixed contracts with authorized buyers beforehand.
The Question of Financial Reimbursement
A central point of the new regime is cost coverage. During the pilot program, medical cannabis expenses were covered by health insurance. With the current transition to the permanent system, authorities, particularly the French health authority, are still negotiating final pricing structures and reimbursement models. For the cannabis industry, this means tough negotiations, as the enormous compliance requirements—such as narcotics law and mandatory medical supervision—drive production costs significantly higher.
New Perspectives for the European Market
With permanent regulation, France establishes itself as one of Europe’s most strictly regulated yet forward-thinking medical cannabis markets. The strict separation between recreational use and purely medical application shows that Paris is taking a highly controlled path. For patients, this means above all product safety and standardized quality, while for companies it remains a challenge to overcome high barriers to entry.
Looking at France demonstrates how varied approaches to medical cannabis remain across Europe in 2026. The coming months will reveal how practical the new prescription pathways prove for patients in everyday life and whether the strict requirements will stand the test of practice.
Sollte Medizinalcannabis nur als letzte Option verschrieben werden dürfen?
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
